Clinical Trial Update: A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing RAY1225 to semaglutide as add-on therapy for type 2 diabetes is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• OZEMPIC (semaglutide)
• RAY1225

Snippet

Sponsor: Guangdong Raynovent Biotech Co., Ltd | Conditions: T2DM | Phase 3 | Status: NOT_YET_RECRUITING